Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0421
Trial ID NCT03434769
Disease Non-Hodgkin's Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD19 CAR-T cells
Generation2nd
PhasePhase1
Recruitment statusActive, Not Recruiting
TitleAntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
Year2018
CountryUnited States
Company sponsorCase Comprehensive Cancer Center
Other ID(s)CASE2417

Clinical Result

Cohort 1
Administration route None
Dosage 1E5 cells/kg, 5E5 cells/kg, 1E6 cells/kg, 2E6 cells/kg
Pts 23
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 16/22(CR); 2/22(PR). Complete responders one-year survival is 92.9%.
Adverse reactions 5/23(immune effector cell-associated neurotoxicity syndrome); 15/23(Anemia); 21/23(thrombocytopenia)
References PMID: 34893603

Relationship Graph

Overview of Knowledge Graph